Humacyte, Inc. (HUMA) News
Filter HUMA News Items
HUMA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
HUMA News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest HUMA News From Around the Web
Below are the latest news stories about HUMACYTE INC that investors may wish to consider to help them evaluate HUMA as an investment opportunity.
Humacyte price target raised to $17 from $15 at BenchmarkBenchmark analyst Bruce Jackson raised the firm’s price target on Humacyte (HUMA) to $17 from $15 and keeps a Buy rating on the shares. Humacyte announced it received full FDA approval for SYMVESS for use in adults as a a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and when autologous vein graft is not feasible, and the final labeling removes any reference to synthetic graft material, which is better than expected, the analy |
High Growth Tech Stocks to Watch in December 2024Over the last 7 days, the United States market has dropped by 2.7%, yet it has risen by an impressive 23% over the past year, with earnings forecasted to grow by 15% annually. In this context of robust annual growth despite recent fluctuations, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability in a dynamic market environment. |
Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma– SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair – – In clinical testing SYMVESS was observed to have high rates of patency, or blood flow, and low rates of amputation and infection – – Highly experienced sales team already recruited and trained in preparation for commercial launch – DURHAM, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a biotechnology platform co |
Individual investors who have a significant stake must be disappointed along with institutions after Humacyte, Inc.'s (NASDAQ:HUMA) market cap dropped by US$60mKey Insights Humacyte's significant individual investors ownership suggests that the key decisions are influenced by... |
Humacyte to Present at the Piper Sandler 36th Annual Healthcare ConferenceDURHAM, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, will participate in a fireside chat presentation at the Piper Sandler 36th Annual Healthcare Conference, in New York, NY on Thursday, December 5, 2024. Management will also be available for |
Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)DURHAM, N.C., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that it will present Phase 3 results from a clinical study comparing efficacy and safety of Humacyte's acellular tissue engineered vessel (ATEV™) with autologous AV fistulas in patients with end stage renal disease at the 51st Annual Symposium on Vascular and Endovascular |
Insider Buyers At Humacyte Likely Disappointed With 17% SlideInsiders who acquired US$775.1k worth of Humacyte, Inc.'s ( NASDAQ:HUMA ) stock at an average price of US$6.64 in the... |
Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery– In two studies the acellular tissue engineered vessel (ATEV) provided benefits in terms of patency, limb salvage, and infection resistance compared to current synthetic graft treatment benchmarks – – Results were published in a premier peer-reviewed surgical journal sponsored by the American Medical Association – DURHAM, N.C., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human |
Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association’s Scientific Sessions 2024– sdATEVs maintained sustained patency throughout the six-month study – – sdATEV was observed to recellularize with host cells and remodel to effectively reduce the initial size mismatch between the sdATEV and the animal’s native artery – DURHAM, N.C., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced the presentation of positive preclinical |
Humacyte Announces Pricing of $15.0 Million Registered Direct OfferingDURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that it entered into a securities purchase agreement with an institutional investor to purchase approximately $15.0 million worth of its common stock and warrants to purchase common stock in a registered direct offering. Under the terms of the securities purchase agreement |